NEOGALFARM: Development of therapies and combined treatments directed at different therapeutic targets

New drugs against cancer: Development of therapies and combined treatments directed at different therapeutic targets

GalChimia is part of the Neogalfarm project. Its objective is the identification of new treatments for oncology, using new therapeutic targets as well as combined therapies. The project emerged from a collaboration between AMSlab, NANOGAP, Oncostellae, and several research groups from the University of Santiago de Compostela (USC), the Health Research Institute of Santiago de Compostela (IDIS), and LEITAT.

This project was granted by the Innovation Galician Agency (GAIN) through the Conecta Pyme Program, co-financed by the European Regional Development Fund (ERDF) and supported by the Consellería de Economía, Emprego e Industria (Xunta de Galicia). The total budget is 1,076,339.63 euros.

Comunication and Dissemination

• Poster DEVELOPMENT OF NOVEL DRUG CANDIDATES FOR SELECTIVE INHIBITION OF Bcl-2 PROTEIN–PROTEIN INTERACTIONS presented at the SEQT National Congress (Santiago de Compostela, 2022).

GalChimia thanks all the partners in the Neogalfarm project for their involvement and teamwork, which have been key to the success of the project.